Protalix Biotherapeutics Inc. Daily Stock Analysis

Daily Stock Analysis, PLX, Protalix Biotherapeutics Inc, priceseries

Protalix Biotherapeutics Inc. Daily Stock Analysis
Stock Information
Open
0.85
Close
0.85
High
0.88
Low
0.83
Previous Close
0.88
Daily Price Gain
-0.03
YTD High
1.14
YTD High Date
Feb 8, 2022
YTD Low
0.70
YTD Low Date
Feb 24, 2022
YTD Price Change
-0.06
YTD Gain
-6.58%
52 Week High
6.64
52 Week High Date
Apr 26, 2021
52 Week Low
0.70
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-3.47
52 Week Gain
-80.32%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 27. 2016
3.53
Jan 11. 2017
4.06
10 Trading Days
15.02%
Link
LONG
Jan 13. 2017
4.30
Feb 17. 2017
9.98
24 Trading Days
132.10%
Link
LONG
Mar 10. 2017
11.80
Mar 15. 2017
12.45
3 Trading Days
5.51%
Link
LONG
Oct 16. 2017
6.00
Oct 30. 2017
6.88
10 Trading Days
14.66%
Link
LONG
Sep 12. 2018
4.93
Oct 5. 2018
6.90
17 Trading Days
39.86%
Link
LONG
Jan 2. 2019
3.40
Jan 30. 2019
4.24
19 Trading Days
24.84%
Link
LONG
Jan 31. 2019
4.86
Feb 5. 2019
5.28
3 Trading Days
8.64%
Link
LONG
Nov 21. 2019
2.34
Dec 12. 2019
2.89
14 Trading Days
23.52%
Link
LONG
Dec 27. 2019
2.79
Jan 14. 2020
3.71
11 Trading Days
33.06%
Link
LONG
Apr 6. 2020
2.33
Apr 30. 2020
3.96
17 Trading Days
70.10%
Link
LONG
Jan 13. 2021
3.80
Jan 28. 2021
4.25
10 Trading Days
11.88%
Link
LONG
Feb 1. 2021
4.41
Feb 12. 2021
5.04
9 Trading Days
14.29%
Link
LONG
Aug 25. 2021
1.48
Sep 10. 2021
1.56
11 Trading Days
5.59%
Link
Company Information
Stock Symbol
PLX
Exchange
NYSE MKT
Company URL
http://www.protalix.com
Company Phone
972-4-988-9488
CEO
Moshe Manor
Headquarters
-
Business Address
2 SNUNIT ST, SCIENCE PARK, POB 455, CARMIEL, ISRAEL 20100
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001006281
About

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system. It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease. Its drug candidates also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases such as rheumatoid, psoriatic and juvenile idiopathic arthritis, ankylosing, spondylitis, and plaque psoriasis; and protein for biodefense and other indications. The company was founded on November 30, 1995 and is headquartered in Carmiel, Israel.

Description

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is marketed under the ELELYSO brand name, as an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in Phase III clinical trial to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant human Deoxyribonuclease 1 that is in Phase II clinical trial to treat cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase II clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Carmiel, Israel.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading